Design and immunological evaluation of anti-CD205-tailored PLGA-based nanoparticulate cancer vaccine

Sheikh Tasnim Jahan, Sams MA Sadat, Azita Haddadi Division of Pharmacy, College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada Abstract: The aim of this research was to develop a targeted antigen–adjuvant assembled delivery system that will enable dendritic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jahan ST, Sadat SMA, Haddadi A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Nanoparticle Ovalbumin MPLA anti-CD205 PLGA dendritic cells Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/b5a225a286504be99eb19ccf40aa7ec8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b5a225a286504be99eb19ccf40aa7ec8
record_format	dspace
spelling	oai:doaj.org-article:b5a225a286504be99eb19ccf40aa7ec82021-12-02T01:58:49ZDesign and immunological evaluation of anti-CD205-tailored PLGA-based nanoparticulate cancer vaccine1178-2013https://doaj.org/article/b5a225a286504be99eb19ccf40aa7ec82018-01-01T00:00:00Zhttps://www.dovepress.com/design-and-immunological-evaluation-of-anti-cd205-tailored-plga-based--peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Sheikh Tasnim Jahan, Sams MA Sadat, Azita Haddadi Division of Pharmacy, College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada Abstract: The aim of this research was to develop a targeted antigen–adjuvant assembled delivery system that will enable dendritic cells (DCs) to efficiently mature to recognize antigens released from tumor cells. It is important to target the DCs with greater efficiency to prime T cell immune responses. In brief, model antigen, ovalbumin (OV), and monophosphoryl lipid A adjuvant were encapsulated within the nanoparticle (NP) by double emulsification solvent evaporation method. Targeted NPs were obtained through ligand incorporation via physical adsorption or chemical conjugation process. Intracellular uptake of the NPs and the maturation of DCs were evaluated with flow cytometry. Remarkably, the developed delivery system had suitable physicochemical properties, such as particle size, surface charge, OV encapsulation efficiency, biphasic OV release pattern, and safety profile. The ligand modified formulations had higher targeting efficiency than the non-tailored NPs. This was also evident when the targeted formulations expressed comparatively higher fold increase in surface activation markers such as CD40, CD86, and major histocompatibility complex class II molecules. The maturation of DCs was further confirmed through secretion of extracellular cytokines compared to control cells in the DC microenvironment. Physicochemical characterization of NPs was performed based on the polymer end groups, their viscosities, and ligand-NP bonding type. In conclusion, the DC stimulatory response was integrated to develop a relationship between the NP structure and desired immune response. Therefore, the present study narrates a comparative evaluation of some selected parameters to choose a suitable formulation useful for in vivo cancer immunotherapy. Keywords: nanoparticle, immunotherapy, ovalbumin, monophosphoryl lipid A, dendritic cells Jahan STSadat SMAHaddadi ADove Medical PressarticleNanoparticleOvalbuminMPLAanti-CD205PLGAdendritic cellsMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 13, Pp 367-386 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Nanoparticle Ovalbumin MPLA anti-CD205 PLGA dendritic cells Medicine (General) R5-920
spellingShingle	Nanoparticle Ovalbumin MPLA anti-CD205 PLGA dendritic cells Medicine (General) R5-920 Jahan ST Sadat SMA Haddadi A Design and immunological evaluation of anti-CD205-tailored PLGA-based nanoparticulate cancer vaccine
description	Sheikh Tasnim Jahan, Sams MA Sadat, Azita Haddadi Division of Pharmacy, College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada Abstract: The aim of this research was to develop a targeted antigen–adjuvant assembled delivery system that will enable dendritic cells (DCs) to efficiently mature to recognize antigens released from tumor cells. It is important to target the DCs with greater efficiency to prime T cell immune responses. In brief, model antigen, ovalbumin (OV), and monophosphoryl lipid A adjuvant were encapsulated within the nanoparticle (NP) by double emulsification solvent evaporation method. Targeted NPs were obtained through ligand incorporation via physical adsorption or chemical conjugation process. Intracellular uptake of the NPs and the maturation of DCs were evaluated with flow cytometry. Remarkably, the developed delivery system had suitable physicochemical properties, such as particle size, surface charge, OV encapsulation efficiency, biphasic OV release pattern, and safety profile. The ligand modified formulations had higher targeting efficiency than the non-tailored NPs. This was also evident when the targeted formulations expressed comparatively higher fold increase in surface activation markers such as CD40, CD86, and major histocompatibility complex class II molecules. The maturation of DCs was further confirmed through secretion of extracellular cytokines compared to control cells in the DC microenvironment. Physicochemical characterization of NPs was performed based on the polymer end groups, their viscosities, and ligand-NP bonding type. In conclusion, the DC stimulatory response was integrated to develop a relationship between the NP structure and desired immune response. Therefore, the present study narrates a comparative evaluation of some selected parameters to choose a suitable formulation useful for in vivo cancer immunotherapy. Keywords: nanoparticle, immunotherapy, ovalbumin, monophosphoryl lipid A, dendritic cells
format	article
author	Jahan ST Sadat SMA Haddadi A
author_facet	Jahan ST Sadat SMA Haddadi A
author_sort	Jahan ST
title	Design and immunological evaluation of anti-CD205-tailored PLGA-based nanoparticulate cancer vaccine
title_short	Design and immunological evaluation of anti-CD205-tailored PLGA-based nanoparticulate cancer vaccine
title_full	Design and immunological evaluation of anti-CD205-tailored PLGA-based nanoparticulate cancer vaccine
title_fullStr	Design and immunological evaluation of anti-CD205-tailored PLGA-based nanoparticulate cancer vaccine
title_full_unstemmed	Design and immunological evaluation of anti-CD205-tailored PLGA-based nanoparticulate cancer vaccine
title_sort	design and immunological evaluation of anti-cd205-tailored plga-based nanoparticulate cancer vaccine
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/b5a225a286504be99eb19ccf40aa7ec8
work_keys_str_mv	AT jahanst designandimmunologicalevaluationofanticd205tailoredplgabasednanoparticulatecancervaccine AT sadatsma designandimmunologicalevaluationofanticd205tailoredplgabasednanoparticulatecancervaccine AT haddadia designandimmunologicalevaluationofanticd205tailoredplgabasednanoparticulatecancervaccine
_version_	1718402798516699136

Design and immunological evaluation of anti-CD205-tailored PLGA-based nanoparticulate cancer vaccine

Ejemplares similares